May 20th 2024
During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Immune Checkpoint Approaches in AML and MDS: A Next Frontier?
March 7th 2017The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.
Read More
Ruxolitinib Demonstrates Safety, Efficacy in Myelofibrosis, Expanded Access Trial Confirms
February 28th 2017Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.
Read More
Axicabtagene Ciloleucel Demonstrates Safety and Efficacy in Lymphoma
February 10th 2017Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3ζ/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.
Read More
Study Shows Prevalence of Ph-like ALL in Adults Necessitates Targeted Clinical Trials
February 8th 2017Philadelphia chromosome Ph–like acute lymphoblastic leukemia accounts for more than 20% of all adult patients with ALL and is associated with a poor outcome, according to findings published in the Journal of Clinical Oncology.
Read More
Preliminary Efficacy Seen With MOR208 Combo Regimens in CLL
January 27th 2017Lead study author Jennifer A. Woyach, MD, discusses a phase II trial of MOR208, which includes cohorts of patients with relapsed/refractory CLL, treatment-naïve disease, Richter’s transformation, and those with CLL who have been treated with ibrutinib.
Read More